Industries > Pharma > Ophthalmic Drugs Market Forecast 2014-2024

Ophthalmic Drugs Market Forecast 2014-2024

Prospects for Leading Companies

PUBLISHED: 16 June 2014
PAGES: 337
PRODUCT CODE:
SUBMARKET: Therapeutic Drugs

Clear
WOOCS 2.2.1
SKU: N/A Categories: ,

Ophthalmic drugs – new study showing you trends, R&D progress, and predicted revenues
Where is the ophthalmic drugs market heading? Visiongain’s brand new report shows you potential revenues to 2024, assessing data, trends, opportunities and prospects there.

Our 337-page report provides 198 tables, charts, and graphs. Discover the most lucrative areas in the industry and the future market prospects. Our new study lets you assess forecasted sales at overall world market and national level. You will see financial results, interviews, trends, opportunities, and revenue predictions. Much opportunity remains in this growing pharma market.

Forecasts from 2014-2024 and other analyses show you commercial prospects
Besides revenue forecasting to 2024, our new study provides you with recent results, growth rates, and market shares. There you find original analyses, with business outlooks and developments. Discover qualitative analyses (including SWOT and Porter’s Five Forces Analysis), company profiles and commercial developments. Read the full transcripts of ten exclusive expert opinion interviews from industry specialists informing your understanding and allowing you to assess prospects for investments and sales, including:
• Cathy Yelf, Head of External Relations, Macular Society
• RNIB (Royal National Institute of Blind People)
• Charles C Wykoff, Dr, Retina Consultants of Houston
• Manju Subramanian, Associate Professor, Boston University School of Medicine
• Vanda Pharmaceuticals
• Professor David T. Shima, PhD, Institute of Ophthalmology, University College London
• Anonymous interview
• Sean Ainsworth, CEO and Founder of RetroSense Therapeutics
• Philip G. Ralston, Jr., CEO of MacuCLEAR
• Dr Michael Stewart, Associate Professor, Mayo Clinic

Discover sales predictions for the world market and submarkets
Along with revenue prediction for the overall world market, you see forecasts to 2024 for these five submarkets:
• Retinal disorders
• Allergic, inflammatory and infective drugs
• Glaucoma
• Dry eye
• Other treatments.

Our investigation discusses what stimulates and restrains business. You find dynamics of the industry and assess its potential sales, seeing agents likely to achieve the most success.

See revenue forecasts for products
How will leading drugs perform to 2024 at world level? Our study forecasts sales of 26 products, including these brands:
• Lucentis
• Eylea
• Restasis
• Lumigan and Ganfort
• Xalatan/Xalacom
• Travatan/Travatan Z and DuoTrav
• Alphagan/Alphagan P and Combigan
• Refresh brand products
• Pataday
• Vigamox

Discover how high revenues can go. You see what's happening, understanding trends, challenges and opportunities.

Our analysis also breaks the main world forecast into geographical markets.

What are the prospects in the leading regions and countries?
In addition to analyses of the overall world market, you discover individual revenue forecasts for 12 leading national markets to 2024:
• US
• Japan
• China
• Germany
• France
• UK
• Italy
• Spain
• India
• Brazil
• Russia
• Mexico
• Rest of the World

There will be growth in established pharma markets and in developing countries. Our analyses show that India, China, Mexico and Brazil, in particular, will continue to achieve high revenue growth to 2024. Developments worldwide in product approval and pricing will influence the market.

Leading companies and potential for market growth
Overall world revenue for ophthalmic drugs will reach $20.9bn in 2014, our work forecasts. We predict steady revenue growth from 2014 to 2024. Rising demand for ophthalmic drugs, expanding healthcare coverage, the strength of the R&D pipeline and developments in drug delivery technologies will increase sales to 2024.

Our work shows you what organisations hold greatest potential. See profiles of 10 leading companies, including these:
• Novartis (Alcon)
• Allergan
• Roche
• Valeant (including Bausch & Lomb)
• Regeneron
• Santen
• Pfizer
• Merck & Co.
• Bayer
• Senju

A company profile gives you the following information:
• Revenue forecast for ophthalmic drugs from 2014 to 2024
• Discussion of a company’s activities and outlook
• Recent financial results
• Assessment of recent developments – mergers and acquisitions (M&A), new products, and collaborations, including alliances, partnerships and joint ventures

Discover capabilities, progress, and commercial prospects, helping you stay ahead.

Research and development – assess innovation, trends and possibilities
What about R&D – the pipeline for new drugs? You see trends for these areas:
• Retinal disorders
• Allergic, inflammatory and infective drugs
• Glaucoma
• Dry eye
• Other progress in ophthalmology.

Our study also discusses these agents and technologies, among others:
• Drug delivery
• Oral drug candidates
• Novel small molecules
• Gene therapy.

Ophthalmology holds strong, promising R&D. Novel compounds and new formulations with high safety, efficacy and affordability are in great demand. Our work explains, discussing many issues.

What issues will affect the ophthalmic drugs industry?
Our new report discusses issues and events affecting the ophthalmic drugs market. You will find discussions, including qualitative analyses:
• Increasing demand for ophthalmic drugs due to demographic trends
• A strong R&D pipeline
• Patent expiry and generic competition
• Growth areas such as wet AMD and dry eye
• Advances in topical drug delivery
• Sustained-release ocular implants
• Pricing and reimbursement issues

You will see discussions of technological, commercial, and economic matters, with emphasis on the competitive landscape and business outlooks.

How the Ophthalmic Drugs Market Forecast 2014-2024: Prospects for Leading Companies report helps you
In summary, our 337-page report gives you the following knowledge:
Revenues forecast to 2024 for the world ophthalmic drugs market and 5 product categories (therapeutic classes) – discover the industry’s prospects, finding promising places for investments and revenues
Revenue forecasts to 2024 for the leading 12 national markets – US, Japan, China, Germany, France, UK, Italy, Spain, India, Brazil, Russia, Mexico and Rest of the World
Assessment of 10 leading companies – hear about products, results and strategies including revenue forecasts for ophthalmic drugs to 2024
Predicted revenues of 26 leading ophthalmic drugs to 2024 – see potentials of top products
Review of R&D pipelines – investigate developmental trends and progress
Discussion of what stimulates and restrains companies and the market
Prospects for established firms and those seeking to enter the market
View opinions from our survey, seeing interviews with ten leading authorities

You will find quantitative and qualitative analyses with independent predictions. You will receive information that only our report contains, staying informed with this invaluable business intelligence.

Information found nowhere else
With our survey you are less likely to fall behind in knowledge or miss opportunity. See how you could benefit your research, analyses, and decisions. Also see how you can save time and receive recognition for commercial insight.

Visiongain’s study is for everybody needing commercial analyses for the ophthalmic drugs market and leading companies. You find data, trends and predictions. Please order our report now.

Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6

Download sample pages

Complete the form below to download your free sample pages for Ophthalmic Drugs Market Forecast 2014-2024


Download sample pages

Complete the form below to download your free sample pages for Ophthalmic Drugs Market Forecast 2014-2024


Latest Pharma news

Visiongain Publishes Direct-to-Patient Market Report 2021-2031

Over the last few years, Direct-to-Patient has gained widespread attention. DTP companies offer their customers, who are patients, in this case, all kinds of services.

21 July 2021

READ

Visiongain Publishes Drug Delivery Technologies Market Report 2021-2031

Rising geriatric population, increasing prevalence of chronic and infectious diseases, escalating investment in drug R&D by biopharmaceutical companies, rising demand for advanced drug delivery technologies for chronic treatment are some of the major factors that drive the growth of the global drug delivery technologies market.

20 July 2021

READ

Visiongain Publishes Pharma Contract Sales Market Report 2021-2031

Pharma services companies are widening their service offerings (either organically or inorganically through M&A) to become full-service providers, simplifying their customers’ operations and gaining the maximum share of their outsourcing budgets, driven by the willingness of pharma to reduce the number of outsourcers they use.

14 July 2021

READ

Visiongain Publishes Clinical Trial Supply and Logistics Market for Pharma 2021-2031

Digital innovation in clinical trials and renewed focus on home production will ensure a high growth market for supply chain optimisation.

12 July 2021

READ

Categories